efgartigimod alfa   

GtoPdb Ligand ID: 9777

Synonyms: ARGX-113
Compound class: Antibody
Comment: Efgartigimod alfa (ARGX-113) is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G (IgG) autoantibodies [6]. It binds to the IgG receptor, major histocompatibility complex class I-like Fc receptor (FcRn, the protein product of the FCGRT gene). Efgartigimod alfa inactivates FcRn's IgG binding ability (the FcRn-IgG interaction normally protects IgG from degradation) thus facilitating accelerated catabolism of native pathogenic autoantibodies [3,5]. The mechanism of this drug action is discussed more comprehensively in Roopenian and Akilesh (2007) [4] and Vaccaro et al. (2005) [7].
No information available.
Summary of Clinical Use
ARGX-113 has completed Phase 2 trial in patients with myasthenia gravis (MG), and will be evaluated in separate Phase 2 clinical trials for pemphigus vulgaris and primary immune thrombocytopenia. Click here to view ClinicalTrials.gov's registered ARGX-113 trials. ARGX-113 was granted FDA orphan drug designation for the treatment of MG in September 2017 [1].